PRRTInfo.org - A Resource for Patients Considering PRRT Treatment.
|
PRRTinfo.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients. While much of this information can be used by patients seeking treatment at any PRRT Center worldwide, this site focus is on the treatment as provided by Dr. Richard Baum and his team at the Zentralklinik Bad Berka in Bad Berka, Germany.
As with any site that offers information on treatment or travel, please confirm medical information with your medical team, as well as any travel information with the travel providers.
PRRTInfo.org is focused on treatment at the Zentralklink. We provide links to a select number of other medical centers that offer PRRT which can be found here.
All articles on this website can be printed, emailed or downloaded to a PDF file for reference when Internet connectivity is not available. Just click on the appropriate icon in the upper right hand corner of the article. If you see a picture you like, click on the zoom icon in the lower right hand corner of the picture for a full screen version of the picture. In this mode you can also scroll through the photos in a particular article by selecting next or previous in the lower left hand corner of the picture.
We look forward to your feedback.
|
|
|
The First World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT) was held in Bad Berka on June 23-26, 2011. Attended by over 400 medical professional from more than 50 countries from every corner of the world. During the two and a half day event over 80 presentations were given on the chemistry of gallium 68 (Ga68) and its production, the use of Ga68 in imaging, and the treatment of Neuroendocrine Tumors (NETs) using Peptide Receptor RadioNuclide Thearpy (PRRNT). The event was orginized by Prof. Dr. Richard P. Baum of Zentralklink, Bad Berka and Prof. Dr. Frank Rösch of the Institute of Nuclear Chemistry, Johannes Gutenberg University.
|
|
Read more...
|
|
The 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) took place on June 23-26, 2011 in Bad Berka, Germany. This Congress, co-organised by the Department of Nuclear Medicine/PET Center, Zentralklinik Bad Berka and the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, was targeted to chemists, physicians, and investigators dealing with generators, PET radiochemistry as well as molecular imaging and radionuclide therapy.
The Congress attracted over 400 participants from 53 countries coming from all 5 continents. In addition to the official programme, there were a number of social and cultural events.
The Congress organizers have provided access to audio and video recordings of the three day event that was expertly recorded by ITR8. Please click here to be taken to the presentation site. Enjoy! |
|
On April 10, 2012 a 42 center worldwide trial of PRRT using LU177 was announced with sites in the US and Europe.
Detailed Description:
A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours; these patients should be progressive under Octreotide LAR. In case patients in either arm experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections are allowed. Objective tumour response in both arms will be assessed every 12±1 weeks from the first treatment date according to RECIST Criteria. The baseline CT scan/MRI must not be older than 4 weeks before the projected randomization date.
For completes information including participating centers click here to be taken to Clinicaltrials.gov
|
|
|
|
|
|
|
Page 1 of 2 |
Subscribe to RSS Feed
